Cancer Progress 2026 Key Highlights

Cancer Progress returned to New York City in person on April 9, 2026, in support of the Damon Runyon Cancer Research Foundation. The program convened leading oncology experts for a candid, forward-looking discussion of the challenges and breakthroughs, reshaping cancer care, underscoring the role of collaboration in turning scientific progress into meaningful patient impact. Below are the key takeaways from each panel discussion.

Patient Centric Innovations: Transforming Cancer Care

Summary: This panel explored the shift from one-size-fits-all oncology to truly personalized cancer care. Lived experience experts and caregivers shared how tools like genomic testing, biomarker-driven therapies, and more flexible trial designs are changing the cancer journey, enabling earlier detection, more precise treatment decisions, and more holistic support. The discussion also highlighted how patient and caregiver voices are shaping research priorities, care delivery models, and technology adoption, while acknowledging the practical challenges of making personalized care accessible and consistent across settings.

Key Takeaways:

Personalized cancer care depends on access to the right precision diagnostics (e.g., advanced imaging/genomic testing), second opinions, and clinicians who listen, these factors can materially change outcomes.
Clinical trials should be introduced earlier and more transparently; patients shouldn’t have to self-advocate to learn their options, and patient advocates can help demystify participation.
Human-centered, multidisciplinary care improves both treatment decisions and quality of life, supporting the whole person during and after therapy.
Panelists emphasized that surviving cancer is the bare minimum threshold. Cancer progress should aim for the ceiling, ideally helping people thrive while living with or beyond cancer.
AI and technology can help organize information (including trial and treatment options), but must be paired with ethics, privacy, and human judgment—not replace clinician accountability or compassion.

Driving First & Best-in-Class Innovation: Balancing Technical and Commercial Risk Early

Summary: This panel unpacked how early oncology biotechs can pursue first-in-class or best-in-class innovation in an increasingly crowded, fast-moving market, where novelty alone is no longer enough. Speakers emphasized that early commercial thinking should sharpen scientific choices by setting stakeholder-relevant TPP thresholds, pressure-testing differentiation against future (not current) competitors, and building a clear value narrative for funders and partners. The discussion also highlighted what truly de-risks programs: credible translational logic, manufacturability, and ultimately compelling human efficacy, while warning against relying on FOMO-driven strategies (although FOMO can be leveraged with good assets) and being willing to drop “zombie” programs that drain capital without a clear line of sight to addressing unmet needs and hence ROI.

Key Takeaways:

First-in-class/best-in-class is about clinical impact, not just novelty: differentiation increasingly sits on a spectrum (target, modality, line, combo context), and “incremental” can still win if it shifts prescribing, payer behavior, convenience, or delivery.
Competition raises the bar and the clock is always moving: programs must benchmark against future standards and emerging modalities, with lifecycle strategy and resourcing often determining winners as much as molecule quality (including rising pressure from China–led acceleration in ADCs and other platforms).
Early programs must tell a crisp, translatable story: investors/partners look for a clear thesis, pharma-like developability/manufacturability, and preclinical readouts that credibly project to humans.
Human data is the ultimate de-risking event: strong clinical activity outweighs everything else, and big pharma will vary by portfolio need so pitches must be partner-specific, not generic.
Avoid simplistic chasing of FOMO and preserve capital: hot areas can facilitate partnering/funding, but building on the assumption that minimal data will trigger a deal or a raise is risky; biotechs should focus on compelling differentiation in preclinical and clinical data, and be willing to kill early those programs that fail to meet a robust threshold, rather than endlessly pushing “zombie” assets that don’t support the value proposition.
Avoid narrative of discount pricing strategies.

Beyond the Mainstream: Addressing Neglected Tumor Types

Summary: This panel explored why certain rare and aggressive cancers, such as GBM and sarcoma, as well as other historically underfunded tumor types, remain “neglected” despite broader oncology innovation. The group emphasized that neglect is driven less by lack of scientific interest and more by structural barriers: fragmented ultra-rare populations, heterogeneous biology, weak standards of care, diagnostic gaps, and difficult trial execution. Panelists discussed how progress will depend on feasible, information-rich trial designs, earlier and clearer regulatory alignment, and intentional access/accrual planning through strong partnerships with expert centers and patient advocates, alongside early market access thinking.

Key Takeaways:

Neglect is multifactorial and often structural: challenges include complex/heterogeneous biology (e.g., many sarcoma subtypes), late diagnosis and difficult disease settings (e.g., GBM and other hard-to-detect tumors), and tiny, fragmented patient populations that make development and evidence generation harder.
Funding gaps reinforce the cycle of neglect: several tumor types (including uterine/endometrial, cervical, liver, bile duct, and pancreatic cancers) are persistently cited as receiving disproportionately low nonprofit and federal funding, limiting sustained discovery and trial infrastructure.
Trial feasibility and accrual must be designed in, not hoped for: with few expert centers and high travel burden, sponsors need early alignment with investigators, sites/CROs, and patient advocacy groups to reduce burden, improve access, and make rare-disease studies recruitable.
Regulatory success requires rigor and proactive engagement: rare/heterogeneous diseases often require complex trial designs and a clearly articulated evidence package; panelists also noted that FDA staffing/leadership transitions can create institutional knowledge gaps, making early, explicit alignment even more important.
Use broader evidence intelligently to accelerate development: sponsors should consider innovative designs that incorporate validated PROs/QoL, biomarkers/PD, and, where appropriate, RWE and synthetic controls to strengthen comparators, while ensuring endpoints reflect clinically meaningful benefit for patients (symptom relief, PFS, survival).

Raising the Bar: How Biotech Can Meet the Challenge

Summary: This panel addressed how early-stage oncology biotechs can compete and grow in a tougher capital environment, where investor enthusiasm has cooled, the bar for differentiation has risen, and global competition (especially from China) is reshaping speed and cost expectations. Speakers described a market reset driven by fatigue with high-spend/low-yield strategies (notably broad IO combinations) and a renewed focus on clear de-risking signals, interpretable early clinical data, and disciplined capital deployment. The discussion highlighted where interest is clustering, why platforms still matter, and how operating/partnering models may evolve as China becomes more integrated into the global oncology ecosystem.

Key Takeaways:

Oncology sentiment is “selective,” not hot: The days when oncology was by far the largest therapeutic area for VC and pharma are in the past, but oncology remains a major area of activity. In this new era, investors are prioritizing programs with clear early de-risking signals and interpretable Phase 1 readouts, often favoring targeted therapies over broad immuno-oncology strategies.
The sector is refocusing on ROI and credibility: Disappointing returns in parts of precision oncology and repeated PD-1 combination plays have created fatigue; single high-profile setbacks can taint whole mechanisms/targets (e.g., halo effects like TIGIT). Deals are still being made, but with greater scrutiny and demands for validation.
Platforms and engineered modalities still matter: The panel affirmed that there remains room and interest among large pharma and investors to bet on new modalities and platform technologies, with particular enthusiasm for bispecifics and in vivo CAR-T. However, the panel stressed that meaningful commitment increasingly requires human clinical validation, not just elegant engineering.
China is now a real competitive force—but also a major partnering opportunity: While public-market comfort may lag behind, the biopharma industry and investors recognize the tremendous progress in China’s capabilities. China’s advantages in speed, scale, and cost-efficient clinical execution are influencing global strategy, with expectations of more licensing/partnership interlinking across Western and Chinese companies.
Are we in a rebound? Possibly, if we stay disciplined: The biotech outlook included signs of improving financing/M&A and some IPO return, but sustained interest will hinge on stage-appropriate differentiation, quality of the next data readout, and capital-efficient operating models.

Beyond “Next-Gen:” How Should We Engineer Future Breakthroughs?

Summary: This panel challenged the field to focus and retool to pursue true oncology breakthroughs: major improvements in cancer patient outcomes, whether built on successive generations of “next-gen” approaches or through new paradigms and “out-of-the-box” thinking. We have succeeded in making breakthroughs in the past, but amid staggering rates of failure—and the cost associated with that—and only in a limited minority of cancer types, leaving tremendous unmet need. The group reflected on key lessons from the past and envisioned ways to improve moving forward, from adopting new mindsets, to leveraging new methods and technologies (including AI), to restructuring investment and development pathways.

Key Takeaways:

We must balance biology-first approaches with selective empiricism: Breakthroughs must be tailored to essential disease biology, and our tools for uncovering that biology are getting more and more powerful. Digging deep on the biology can reveal new targets or unlock gains even on established targets (past examples include HER2, ALK, and BCR-ABL). However, translational gaps mean that some empiric learning remains necessary. We want to reduce our reliance on “throwing spaghetti against the wall”, but we also must recognize that our understanding of biology is far from complete, and we must remain open to the benefits of serendipity.
We must leverage AI pattern recognition and prediction: While recognizing that AI is associated with much hype and a limited track record, the panel affirmed that it is here to stay and has the potential to unlock and accelerate future breakthroughs. For example, in early discovery, AI enables high-dimensional data integration and faster small-molecule design; the clinical pipeline is now burgeoning with drugs designed with AI assistance. In early development, AI shows promise at biomarker/subgroup discovery in small datasets, and improving signal evaluation using digital twins and synthetic control arms. The panel emphasized however that AI’s role is to augment wet-lab and clinical validation, not to replace it.
We must persist in pursuing immuno-oncology: The panel recognized that following the breakthroughs of CTLA-4 and PD-1 checkpoint blockade, there has been little progress and a long litany of failures. Although the panel recognized that translational gaps did require some continued use of empiric approaches, they criticized over-investment in repetitive and simplistic PD-(L)1 + X combination attempts. Some of the past “failures” may even be revived with the right patient selection and combination/sequencing strategies. The path forward would require deeper mechanistic (and AI-assisted) learning to identify predictors of durable responses, enabled by more data-sharing and richer but less burdensome tissue/biopsy strategies.
The development ecosystem may need structural reform: As precision medicine shrinks addressable populations, the traditional Phase 1→3 model risks becoming economically unsustainable without trial-design/regulatory innovation (e.g., platform approaches, synthetic controls/imputation) and more shared infrastructure partnerships across academia, tech, and service providers. Such reforms may also help address incentive structures that lead to proliferation of “me-too” and incremental programs.

Conclusion:

Cancer Progress 2026 reinforced a clear message: delivering the next era of oncology impact will require aligning scientific ambition with patient-defined value and development discipline from day one. Across panels, speakers converged on the need to pair precision tools and smarter evidence generation with more humane, accessible care, so innovation translates into outcomes patients can feel, not just endpoints we can measure. At the same time, biotechs are being pushed to raise the bar on differentiation, capital efficiency, and partner-ready narratives, while tackling areas markets have historically under-incentivized, including neglected tumor types.

This is where Lumanity can help: through our Oncology Center of Excellence, we support teams in translating science into strategy, stress-testing early TPPs and positioning, clarifying value stories for investors/partners, building evidence and trial strategies (including RWE/innovative designs where appropriate), and integrating patient insights into launch-ready access and commercialization plans. The call to action coming out of Cancer Progress is straightforward: bring commercial thinking earlier, keep patients at the center, and use data, biology, and partnerships to make bolder bets, with the right strategic rigor to turn breakthroughs into real-world impact.